Dupilumab Eases Poorly Controlled Atopic Dermatitis in Adolescents Dupilumab Eases Poorly Controlled Atopic Dermatitis in Adolescents
In adolescents with poorly controlled moderate to severe atopic dermatitis (AD), treatment with dupilumab significantly improved signs and symptoms of AD, including pruritus and sleep loss, as well as quality of life with an"acceptable" safety profile in a phase 3 study.Reuters Health Information
This article examines the pathophysiology, epidemiology, heterogeneous clinical presentation, burden, diagnosis, and treatment of adult AD. PMID: 31757234 [PubMed - in process]
Conclusion: The present study shows that analysis of TFV curves based on ATS/ERS guidelines for tidal breath analysis with additional criteria for visual evaluation in awake infants is reliable and can be used in a real-life setting.
Conclusion: It seems that neurocognitive disturbances due to sleep restriction in AD children may be one of the main trigger, especially for attention deficit.
The immediate priority for clinicians managing patients with atopic dermatitis (AD) is treating the disease, particularly the constant itch and sleep disturbance, with its consequential disruption of both home and work life and association with low mood, poorer concentration, and productivity. However, long-term sequelae are important to consider and include those directly related to the atopic march (asthma, allergic rhinoconjunctivitis, and food allergies), the consequences of having a chronic disease, and potential side effects of therapy, particularly topical corticosteroids.
Children with asthma are at risk for poorer sleep outcomes. Urban minority children are disproportionately burdened by poor sleep due to sociocontextual stressors and challenges with asthma regimens. Atopic dermatitis (AD) is highly co-morbid in children with asthma and can further increase risk for poor sleep. Our study goal was to examine the sleep outcomes in urban children with asthma and determine whether AD increased risk for poorer sleep utilizing a group of urban healthy children as controls.
Conclusions: Dupilumab significantly improved disease severity, pruritus, sleep loss and quality of life with an acceptable safety profile. PMID: 31647347 [PubMed - as supplied by publisher]
This article examines the pathophysiology, epidemiology, heterogeneous clinical presentation, burden, diagnosis, and treatment of adult AD.
CONCLUSION: We identified important similarities and differences in the clinical characteristics of adults with psoriasis and AD; these should help clinicians to prioritize and improve patient management. PMID: 31630393 [PubMed - as supplied by publisher]
Conclusion: Dry skin conditions during infancy may predict the subsequent development of AD. Consequently, emollient therapy from birth represents a feasible, safe, and effective approach for AD prevention. Therefore, parental education and the application of moisturizers are recommended as an integral part of AD prevention, treatment, and maintenance. J Drugs Dermatol. 2019;18(10):1020-1027. PMID: 31584781 [PubMed - as supplied by publisher]
Authors: Ferrucci S, Tavecchio S, Berti E, Angileri L Abstract Atopic dermatitis (AD) is a common chronic multifactorial dermatosis that can occurs through different clinical phenotypes although all undergone identical pathogenetic mechanisms such as the Prurigo Nodularis (PN)-like phenotype. Here, we described eleven patients with PN-like atopic dermatitis treated with dupilumab, a human monoclonal IgG4 antibody that inhibits interleukine-4 (IL-4) and interleukine-13 (IL-13). Efficacy outcomes were performed at baseline, at first and fourth months from starting treatment. We collected different scores such as NRSi...